| [1] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
|
| [2] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.
|
| [3] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002.
|
| [4] |
Ahmed ME, Mahmoud AM, Reitano G, et al. Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same?[J]. Eur Urol Open Sci, 2024, 66: 38-45. DOI: 10.1016/j.euros.2024.06.006.
|
| [5] |
Rud E, Noor D, Galtung KF, et al. Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases[J]. Eur Radiol, 2022, 32(12): 8266-8275. DOI: 10.1007/s00330-022-08945-7.
|
| [6] |
Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis[J]. Prostate, 2014, 74(2): 210-216. DOI: 10.1002/pros.22742.
|
| [7] |
|
| [8] |
Moshref L, Abidullah M, Czaykowski P, et al. Prostate cancer metastasis to stomach: a case report and review of literature[J]. Curr Oncol, 2023, 30(4): 3901-3914. DOI: 10.3390/curroncol30040295.
|
| [9] |
|
| [10] |
Labib OH, Harb OA, Khalil OH, et al. The diagnostic value of arginase-1, FTCD, and MOC-31 expression in early detection of hepatocellular carcinoma (HCC) and in differentiation between HCC and metastatic adenocarcinoma to the liver[J]. J Gastrointest Cancer, 2020, 51(1): 88-101. DOI: 10.1007/s12029-019-00211-2.
|
| [11] |
Kanarek N, Keys HR, Cantor JR, et al. Histidine catabolism is a major determinant of methotrexate sensitivity[J]. Nature, 2018, 559(7715): 632-636. DOI: 10.1038/s41586-018-0316-7.
|
| [12] |
Chen J, Chen Z, Huang Z, et al. Formiminotransferase cyclodeaminase suppresses hepatocellular carcinoma by modulating cell apoptosis, DNA damage, and phosphatidylinositol 3-kinases (PI3K)/Akt signaling pathway[J]. Med Sci Monit, 2019, 25: 4474-4484. DOI: 10.12659/MSM.916202.
|
| [13] |
Kaneko Y, Shimoda K, Ayala R, et al. p97 and p47 function in membrane tethering in cooperation with FTCD during mitotic Golgi reassembly[J]. EMBO J, 2021, 40(9): e105853. DOI: 10.15252/embj.2020105853.
|
| [14] |
Tian Y, Lu J, Qiao Y. A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma[J]. Front Mol Biosci, 2022, 9: 988323. DOI: 10.3389/fmolb.2022.988323.
|
| [15] |
Zhang W, Wu C, Ni R, et al. Formimidoyltransferase cyclodeaminase prevents the starvation-induced liver hepatomegaly and dysfunction through downregulating mTORC1[J]. PLoS Genet, 2021, 17(12): e1009980. DOI: 10.1371/journal.pgen.1009980.
|
| [16] |
Xiao J, Wang J, Zhou C, et al. Development and validation of a propionate metabolism-related gene signature for prognostic prediction of hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2023, 10: 1673-1687. DOI: 10.2147/JHC.S420614.
|
| [17] |
Sorli SC, Colié S, Albinet V, et al. The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells[J]. FASEB J, 2013, 27(2): 489-498. DOI: 10.1096/fj.12-215152.
|
| [18] |
Niu C, Li X, et al. Identification of novel prognostic biomarkers for colorectal cancer by bioinformatics analysis[J]. Turk J Gastroenterol, 2024, 35(1): 61-72. DOI: 10.5152/tjg.2024.23264.
|
| [19] |
Taghizadeh E, Heydarheydari S, Saberi A, et al. Breast cancer prediction with transcriptome profiling using feature selection and machine learning methods[J]. BMC Bioinformatics, 2022, 23(1): 410. DOI: 10.1186/s12859-022-04965-8.
|
| [20] |
Liu R, Chu W, Liu X, et al. Establishment of Golgi apparatus-related genes signature to predict the prognosis and immunotherapy response in gastric cancer patients[J]. Medicine (Baltimore), 2024, 103(11): e37439. DOI: 10.1097/MD.0000000000037439.
|
| [21] |
Wheeler S, Sillence DJ. Niemann-pick type C disease: cellular pathology and pharmacotherapy[J]. J Neurochem, 2020, 153(6): 674-692. DOI: 10.1111/jnc.14895.
|
| [22] |
Fu Q, Song X, Liu Z, et al. miRomics and proteomics reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by HDGF/DDX5/β-catenin complex in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(20): 6336-6350. DOI: 10.1158/1078-0432.CCR-16-2813.
|
| [23] |
Jiang H, Fu Q, Song X, et al. HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma[J]. Oncol Lett, 2019, 18(5): 4936-4946. DOI: 10.3892/ol.2019.10812.
|
| [24] |
Salama MF, Liu M, Clarke CJ, et al. PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation[J]. Oncogene, 2019, 38(48): 7311-7328. DOI: 10.1038/s41388-019-0950-z.
|
| [25] |
Liu J, Li J. PKCα and Netrin-1/UNC5B positive feedback control in relation with chemical therapy in bladder cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4): 1712-1717. DOI: 10.26355/eurrev_202002_20346.
|
| [26] |
Sun T, Zhang P, Zhang Q, et al. Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis[J]. Heliyon, 2024, 10(10): e30780. DOI: 10.1016/j.heliyon.2024.e30780.
|
| [27] |
Zhao J, Tian H, Zhao X, et al. PKCα induced the generation of extracellular vesicles in activated platelets to promote breast cancer metastasis[J]. Int J Biol Sci, 2024, 20(10): 3956-3971. DOI: 10.7150/ijbs.89822.
|
| [28] |
|
| [29] |
Guo Y, Bao Y, Ma M, et al. Clinical significance of the correlation between PLCE 1 and PRKCA in esophageal inflammation and esophageal carcinoma[J]. Oncotarget, 2017, 8(20): 33285-33299. DOI: 10.18632/oncotarget.16635.
|